Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 2;5(10):e356.
doi: 10.1038/bcj.2015.78.

Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis

D Esteban  1 , N Tovar  1 , R Jiménez  1 , R Santacruz  1 , T Baumann  1 , M C Pastor  1 , A de la Riva  1 , E Carrera  1 , S Chaves  1 , C Royo  2 , A Navarro  2 , S Rodríguez  3 , C Ayuso  3 , G Riu  4 , N Creus  4 , B Gómez  4 , E Giné  1 , A López-Guillermo  1 , J Delgado  1
Affiliations

Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis

D Esteban et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

JD has received consulting and lecturing fees from Gilead, Janssen, GSK-Novartis, Roche and Celgene. JD has also received research grants from GSK and Roche. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival. Kaplan–Meier curves of all three factors that had a significant on overall survival by multivariate analysis: (a) treatment within a clinical trial (yes vs no); (b) IGHV gene (mutated vs unmutated); and (c) TP53 gene (mutated vs unmutated).
See this image and copyright information in PMC

References

    1. 1Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 2014; 32: 3039–3047. - PMC - PubMed
    1. 2Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174. - PubMed
    1. 3Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223. - PMC - PubMed
    1. 4Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997–1007. - PMC - PubMed
    1. 5Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101–1110. - PubMed

Publication types

LinkOut - more resources